VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
1.470
+0.050 (3.52%)
At close: Jun 27, 2025, 4:00 PM
1.540
+0.070 (4.76%)
After-hours: Jun 27, 2025, 4:39 PM EDT
VivoSim Labs Revenue
In the fiscal year ending March 31, 2025, VivoSim Labs had annual revenue of $144.00K with 32.11% growth. VivoSim Labs had revenue of $51.00K in the quarter ending March 31, 2025, with 75.86% growth.
Revenue (ttm)
$144.00K
Revenue Growth
+32.11%
P/S Ratio
14.43
Revenue / Employee
$11,077
Employees
13
Market Cap
3.77M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VIVS News
- 5 weeks ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 6 weeks ago - VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - GlobeNewsWire
- 7 weeks ago - VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - GlobeNewsWire
- 2 months ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 2 months ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire
- 3 months ago - Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - GlobeNewsWire
- 3 months ago - Organovo Provides Business Update - GlobeNewsWire
- 3 months ago - Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - GlobeNewsWire